Bladder Cancer

Following a patient with bladder cancer who had a partial response to frontline therapy, panelists consider the branching treatment pathway.

Among patients with low-grade, non–muscle invasive bladder cancer, intravesical UGN-102 appears to improve outcomes vs standard surgical treatment in two phase 3 trials.

Investigators of a meta-analysis report no significant difference in outcomes when comparing trimodality therapy and radical cystectomy for the treatment of muscle-invasive bladder cancer.

Genitourinary cancer experts share insight on best practices in educating patients on treatment schedules and adverse events when receiving therapy for advanced bladder cancer.

Focused discussion on the optimal use of radiation therapy strategies, alone or in combination with systemic therapy, for patients with advanced bladder cancer.

Key opinion leaders in bladder cancer consider the evolving role of chemoradiation in patients with node-positive disease.

Expert perspectives on first-line treatment options available to patients with advanced bladder cancer who are ineligible for cisplatin-based chemotherapy.

Centering focus on the first-line treatment armamentarium, key opinion leaders consider factors that aid in the selection of best therapy for patients with advanced bladder cancer.

A brief discussion on supportive care available to patients with bladder cancer and the role it plays within the treatment pathway.

The combination also demonstrates no new safety signals in patients with uresectable or metastatic disease and meets the phase 3 CheckMate-901 study’s primary survival end points.

Shared insight on the standard work-up and staging practices used when a patient presents with newly diagnosed bladder cancer.

Expert panelists review a patient presentation of bladder cancer and consider the typical signs and symptoms that may lead to a diagnosis.

Combining enfortumab vedotin with pembrolizumab yields a manageable safety profile in patients with locally advanced or metastatic urothelial cancer in the phase 1b/2 EV-103 study.

Findings from the phase 3 SWOG S1011 trial highlight no significant differences between extended lymphadenectomy vs standard lymphadenectomy in terms of disease-free survival in patients with muscle-invasive breast cancer.

Pembrolizumab in combination with enfortumab vedotin-ejfv demonstrates a manageable safety profile in the treatment of metastatic urothelial carcinoma in the EV-103 trial.

The overall survival benefit of erdafitinib supports molecular testing of FGFR in all patients with metastatic urothelial carcinoma, according to an expert from University Paris-Saclay in France.

Findings from a retrospective analysis highlight no significant differences in metastasis-free survival in patients with muscle-invasive bladder cancer who received radical cystectomy vs trimodality therapy.

The FDA requests additional data and a safety update regarding N-803 plus BCG as a treatment for patients with BCG-unresponsive non-muscle invasive bladder carcinoma.

An artificial intelligence-based model for detecting lymph node metastases appears to identify tumor micrometastases in bladder cancer that pathologists may miss while classifying patient results as negative.

Data from the phase 2 TITAN-TCC trial suggest that early non-responders with metastatic urothelial carcinoma with PD-L1–positive tumors benefit from nivolumab plus nivolumab/ipilimumab boosts.

Results from cohort K of the phase 1b/2 KEYNOTE-869 trial led to the accelerated approval of enfortumab vedotin plus pembrolizumab in patients with locally advanced or metastatic urothelial cancer who cannot receive cisplatin-based chemotherapy.

Shilpa Gupta, MD, discusses bladder preserving strategies for unfit or young patients, trials assessing immunotherapy combinations, and results from the BLASST-1 trial presented at ASCO GU.

A retrospective study clarifies how the implementation of avelumab maintenance looks in real-world practice, according to an expert from Seattle Cancer Care Alliance.

First-line maintenance with avelumab in locally advanced or metastatic urothelial carcinoma yields efficacy that appears consistent between clinical and real-world settings.

Results from the phase 3 IMvigor130 trial reveal a trend towards overall survival improvement when atezolizumab plus chemotherapy was given to patients with locally advanced or metastatic urothelial carcinoma vs placebo.

An exploratory analysis indicates that overall survival did not improve with the use of single-agent atezolizumab in untreated locally advanced or metastatic urothelial cancer.

Pembrolizumab appears to achieve antitumor activity in terms of disease-free survival in patients with Bacillus calmette-guerin–unresponsive, papillary high–risk, non-muscle invasive bladder cancer.

Extended follow-up findings further support the use of nivolumab as a standard of care in high-risk muscle-invasive urothelial carcinoma following radical resection.

Data from the phase 2 TROPHY-U-01 trial support further evaluation of sacituzumab govitecan in patients with metastatic urothelial cancer following immune checkpoint inhibitor therapy, according to the lead investigator.

Findings from the phase 2 UNITE study indicate that certain biomarkers may help inform clinical decision making and sequencing in patients with advanced urothelial carcinoma.